The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Sundial Growers (SNDL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Sundial Growers is one of 1022 companies in the Medical group. The Medical group currently sits at #16 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. SNDL is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for SNDL's full-year earnings has moved 400% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, SNDL has moved about 111.19% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 2.94% on average. As we can see, Sundial Growers is performing better than its sector in the calendar year.
Looking more specifically, SNDL belongs to the Medical - Drugs industry, which includes 205 individual stocks and currently sits at #161 in the Zacks Industry Rank. This group has lost an average of 11.60% so far this year, so SNDL is performing better in this area.
Investors with an interest in Medical stocks should continue to track SNDL. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Sundial Growers (SNDL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Sundial Growers is one of 1022 companies in the Medical group. The Medical group currently sits at #16 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. SNDL is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for SNDL's full-year earnings has moved 400% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, SNDL has moved about 111.19% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 2.94% on average. As we can see, Sundial Growers is performing better than its sector in the calendar year.
Looking more specifically, SNDL belongs to the Medical - Drugs industry, which includes 205 individual stocks and currently sits at #161 in the Zacks Industry Rank. This group has lost an average of 11.60% so far this year, so SNDL is performing better in this area.
Investors with an interest in Medical stocks should continue to track SNDL. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SNDL - FREE